Roquefort Therapeutics (LON:ROQ) Trading Down 11.1% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ) shares dropped 11.1% on Friday . The stock traded as low as GBX 1.20 and last traded at GBX 1.20. Approximately 219,883 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 1,157,323 shares. The stock had previously closed at GBX 1.35.

Roquefort Therapeutics Stock Performance

The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The stock has a market cap of £2.17 million, a PE ratio of -2.10 and a beta of 0.05. The stock has a 50-day simple moving average of GBX 1.43 and a 200-day simple moving average of GBX 1.64.

Insider Activity

In other news, insider Dr Darrin Disley bought 5,000,000 shares of Roquefort Therapeutics stock in a transaction dated Friday, November 21st. The stock was bought at an average cost of GBX 170 per share, for a total transaction of £8,500,000. 23.53% of the stock is owned by company insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.